Phase 1, Multicentre, Open-label, Dose Finding Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia
An open label, multi centre, three arm, dose finding Phase 1 trial with Forodesine as a
single drug treatment in patients with relapsed CLL to establish dose and duration of
treatment resulting in the best achievable response with Forodesine as a single drug
treatment.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the dose and duration of treatment for the best achievable overall response and partial responders with forodesine in relapsed B-cell chronic lymphocytic leukemia (B-Cll)
Spain: Ethics Committee
BCX1777-110
NCT00646165
July 2008
May 2009
Name | Location |
---|